Literature DB >> 26987291

Immunogenic cell death by oncolytic herpes simplex virus type 1 in squamous cell carcinoma cells.

A Takasu1, A Masui1, M Hamada1, T Imai1, S Iwai1, Y Yura1.   

Abstract

Molecules essential for the induction of immunogenic cell death (ICD) are called damage-associated molecular patterns (DAMPs). The effects of oncolytic herpes simplex virus type 1 (HSV-1) on the production of DAMPs were examined in squamous cell carcinoma (SCC) cells. The cytopathic effects of HSV-1 RH2 were observed in mouse SCCVII cells infected at a high multiplicity of infection (MOI), and the amounts of viable cells were decreased. After being infected with RH2, ATP and high mobility group box 1 (HMGB1) were released extracellulary, while calreticulin (CRT) translocated to the cell membrane. A flow-cytometric analysis revealed an increase in the number of annexin-V and propidium iodide (PI)-stained cells; and the amount of cleaved poly (ADP-ribose) polymerase (PARP) was increased. The killing effect of RH2 was reduced by pan-caspase inhibitor z-VAD-fmk and the caspase-1 inhibitor z-YVAD-fmk, suggesting the involvement of apoptosis and pyroptosis. In C3H mice bearing synergic SCCVII tumors, the growth of tumors injected with the supernatant of RH2-infected cells was less than that of tumors injected with phosphate-buffered saline (PBS). These results indicate that oncolytic HSV-1 RH2 produces DAMPs from SCC cells to induce cell death. This may contribute to the enhancement of tumor immunity by oncolytic HSV-1.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26987291     DOI: 10.1038/cgt.2016.8

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  46 in total

1.  Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway.

Authors:  Laurence Zitvogel; Oliver Kepp; Laura Senovilla; Laurie Menger; Nathalie Chaput; Guido Kroemer
Journal:  Clin Cancer Res       Date:  2010-04-26       Impact factor: 12.531

Review 2.  Rethinking herpes simplex virus: the way to oncolytic agents.

Authors:  Gabriella Campadelli-Fiume; Carla De Giovanni; Valentina Gatta; Patrizia Nanni; Pier-Luigi Lollini; Laura Menotti
Journal:  Rev Med Virol       Date:  2011-05-27       Impact factor: 6.989

3.  Labeling membrane glycoproteins or glycolipids with fluorescent wheat germ agglutinin.

Authors:  Brad Chazotte
Journal:  Cold Spring Harb Protoc       Date:  2011-05-01

4.  Direct vaccination with tumor cells killed with ICP4-deficient HSVd120 elicits effective antitumor immunity.

Authors:  Fabian Benencia; Maria C Courrèges; José R Conejo-García; Alisha Mohammed-Hadley; George Coukos
Journal:  Cancer Biol Ther       Date:  2006-07-18       Impact factor: 4.742

Review 5.  Immunogenic cell death and DAMPs in cancer therapy.

Authors:  Dmitri V Krysko; Abhishek D Garg; Agnieszka Kaczmarek; Olga Krysko; Patrizia Agostinis; Peter Vandenabeele
Journal:  Nat Rev Cancer       Date:  2012-11-15       Impact factor: 60.716

6.  The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma.

Authors:  Ta-Chiang Liu; Taeho Hwang; Byeong-Ho Park; John Bell; David H Kirn
Journal:  Mol Ther       Date:  2008-07-15       Impact factor: 11.454

7.  Reovirus activates human dendritic cells to promote innate antitumor immunity.

Authors:  Fiona Errington; Lynette Steele; Robin Prestwich; Kevin J Harrington; Hardev S Pandha; Laura Vidal; Johann de Bono; Peter Selby; Matt Coffey; Richard Vile; Alan Melcher
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

8.  Anticancer activities of adenine nucleotides in mice are mediated through expansion of erythrocyte ATP pools.

Authors:  E Rapaport; J Fontaine
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

9.  Stepwise release of biologically active HMGB1 during HSV-2 infection.

Authors:  Chloé Borde; Stéphanie Barnay-Verdier; Claire Gaillard; Hakim Hocini; Vincent Maréchal; Joël Gozlan
Journal:  PLoS One       Date:  2011-01-19       Impact factor: 3.240

10.  A novel fusogenic herpes simplex virus for oncolytic virotherapy of squamous cell carcinoma.

Authors:  Hiroo Takaoka; Gen Takahashi; Fumi Ogawa; Tomoaki Imai; Soichi Iwai; Yoshiaki Yura
Journal:  Virol J       Date:  2011-06-10       Impact factor: 4.099

View more
  26 in total

1.  Oncolytic Newcastle disease virus induces autophagy-dependent immunogenic cell death in lung cancer cells.

Authors:  Tian Ye; Ke Jiang; Liwen Wei; Martin P Barr; Qing Xu; Guirong Zhang; Chan Ding; Songshu Meng; Haozhe Piao
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

2.  Role of a Small Molecule in the Modulation of Cell Death Signal Transduction Pathways.

Authors:  Stella Hartmann; David J Nusbaum; Kevin Kim; Saleem Alameh; Chi-Lee C Ho; Renae L Cruz; Anastasia Levitin; Kenneth A Bradley; Mikhail Martchenko
Journal:  ACS Infect Dis       Date:  2018-11-05       Impact factor: 5.084

3.  Role of autophagy in oncolytic herpes simplex virus type 1-induced cell death in squamous cell carcinoma cells.

Authors:  Y Furukawa; A Takasu; Y Yura
Journal:  Cancer Gene Ther       Date:  2017-10-06       Impact factor: 5.987

Review 4.  Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma.

Authors:  Praveen K Bommareddy; Anand Patel; Saamia Hossain; Howard L Kaufman
Journal:  Am J Clin Dermatol       Date:  2017-02       Impact factor: 7.403

5.  β-catenin has potential effects on the expression, subcellular localization, and release of high mobility group box 1 during bovine herpesvirus 1 productive infection in MDBK cell culture.

Authors:  Wenqing Fan; Weifeng Yuan; Xiuyan Ding; Liqian Zhu
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

6.  Associations between Viral Infection History Symptoms, Granulocyte Reactive Oxygen Species Activity, and Active Rheumatoid Arthritis Disease in Untreated Women at Onset: Results from a Longitudinal Cohort Study of Tatarstan Women.

Authors:  Marina I Arleevskaya; Albina Z Shafigullina; Yulia V Filina; Julie Lemerle; Yves Renaudineau
Journal:  Front Immunol       Date:  2017-12-05       Impact factor: 7.561

7.  Immunogenic tumor cell death induced by chemotherapy in patients with breast cancer and esophageal squamous cell carcinoma.

Authors:  Keita Aoto; Kousaku Mimura; Hirokazu Okayama; Motonobu Saito; Shun Chida; Masaru Noda; Takahiro Nakajima; Katsuharu Saito; Noriko Abe; Shinji Ohki; Tohru Ohtake; Seiichi Takenoshita; Koji Kono
Journal:  Oncol Rep       Date:  2017-11-14       Impact factor: 3.906

Review 8.  Presage of oncolytic virotherapy for oral cancer with herpes simplex virus.

Authors:  Yoshiaki Yura
Journal:  Jpn Dent Sci Rev       Date:  2016-11-05

9.  α-Synuclein evokes NLRP3 inflammasome-mediated IL-1β secretion from primary human microglia.

Authors:  Adrianne F Pike; Tatiana Varanita; Maaike A C Herrebout; Bonnie C Plug; Jeroen Kole; René J P Musters; Charlotte E Teunissen; Jeroen J M Hoozemans; Luigi Bubacco; Robert Veerhuis
Journal:  Glia       Date:  2021-01-28       Impact factor: 7.452

10.  Selective Pro-Apoptotic Activity of Novel 3,3'-(Aryl/Alkyl-Methylene)Bis(2-Hydroxynaphthalene-1,4-Dione) Derivatives on Human Cancer Cells via the Induction Reactive Oxygen Species.

Authors:  Pritam Sadhukhan; Sukanya Saha; Krishnendu Sinha; Goutam Brahmachari; Parames C Sil
Journal:  PLoS One       Date:  2016-07-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.